附件 99.2
Arcadia生命科学股份有限公司。
合并资产负债表
(未经审计)
(单位:千美元,以股份数据为单位)
|
|
2024年9月30日 |
|
|
2023年12月31日 |
|
||
资产 |
|
|
|
|
|
|
||
流动资产: |
|
|
|
|
|
|
||
现金及现金等价物 |
|
$ |
3,936 |
|
|
$ |
6,518 |
|
短期投资 |
|
|
2,640 |
|
|
|
5,124 |
|
应收账款及其他应收款,减去坏账准备为 |
|
|
882 |
|
|
|
506 |
|
存货 — 流动 |
|
|
835 |
|
|
|
837 |
|
待售资产 |
|
|
— |
|
|
|
51 |
|
应收票据 — 流动 |
|
|
1,827 |
|
|
|
— |
|
预付费用及其他流动资产 |
|
|
521 |
|
|
|
807 |
|
停业资产 — GoodWheat |
|
|
70 |
|
|
|
1,129 |
|
总流动资产 |
|
|
10,711 |
|
|
|
14,972 |
|
物业和设备,净值 |
|
|
55 |
|
|
|
70 |
|
使用权资产 |
|
|
306 |
|
|
|
792 |
|
存货 — 非流动 |
|
|
— |
|
|
|
196 |
|
无形资产-净额 |
|
|
39 |
|
|
|
39 |
|
应收票据 — 非流动性 |
|
|
3,966 |
|
|
|
— |
|
其他非流动资产 |
|
|
164 |
|
|
|
164 |
|
终止运营的非流动资产 — GoodWheat |
|
|
— |
|
|
|
3,472 |
|
总资产 |
|
$ |
15,241 |
|
|
$ |
19,705 |
|
负债和股东权益 |
|
|
|
|
|
|
||
流动负债: |
|
|
|
|
|
|
||
应付账款和应计费用 |
|
$ |
1,692 |
|
|
$ |
1,910 |
|
到相关方款项 |
|
|
30 |
|
|
|
58 |
|
经营租赁负债 — 当前 |
|
|
346 |
|
|
|
852 |
|
其他流动负债 |
|
|
260 |
|
|
|
270 |
|
已终止业务的流动负债 — GoodWheat |
|
|
— |
|
|
|
500 |
|
总流动负债 |
|
|
2,328 |
|
|
|
3,590 |
|
经营租赁负债 — 非流动 |
|
|
— |
|
|
|
155 |
|
普通股权证和期权负债 |
|
|
764 |
|
|
|
1,257 |
|
其他非流动负债 |
|
|
2,000 |
|
|
|
2,000 |
|
总负债 |
|
|
5,092 |
|
|
|
7,002 |
|
承诺和 contingencies (注14) |
|
|
|
|
|
|
||
股东权益: |
|
|
|
|
|
|
||
普通股,面值0.001美元——授权发行150,000,000股;分别为1,364,940和1,285,337 |
|
|
65 |
|
|
|
65 |
|
追加实收资本 |
|
|
284,919 |
|
|
|
284,515 |
|
累计其他综合收益 |
|
|
117 |
|
|
|
101 |
|
累积赤字 |
|
|
(274,814 |
) |
|
|
(271,840 |
) |
股东权益总额 |
|
|
10,287 |
|
|
|
12,841 |
|
非控制权益 |
|
|
(138 |
) |
|
|
(138 |
) |
股东权益总额 |
|
|
10,149 |
|
|
|
12,703 |
|
总负债和股东权益 |
|
$ |
15,241 |
|
|
$ |
19,705 |
|
1
Arcadia生命科学股份有限公司。
合并损益表和综合损益表
(未经审计)
(以千计,除分享数据和每分享数据外)
|
|
截至9月30日的三个月 |
|
|
截至9月30日的九个月 |
|
||||||||||
|
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
营业收入: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
产品 |
|
$ |
1,537 |
|
|
$ |
1,298 |
|
|
$ |
3,829 |
|
|
$ |
3,667 |
|
许可证 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
10 |
|
总收入 |
|
|
1,537 |
|
|
|
1,298 |
|
|
|
3,829 |
|
|
|
3,677 |
|
运营费用: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
收入成本 |
|
|
1,032 |
|
|
|
818 |
|
|
|
2,136 |
|
|
|
1,996 |
|
研发 |
|
|
24 |
|
|
|
15 |
|
|
|
40 |
|
|
|
55 |
|
无形资产出售收益 |
|
|
— |
|
|
|
— |
|
|
|
(4,000 |
) |
|
|
— |
|
财产和设备的减值 |
|
|
— |
|
|
|
— |
|
|
|
36 |
|
|
|
— |
|
销售、一般及行政费用 |
|
|
2,241 |
|
|
|
1,862 |
|
|
|
6,986 |
|
|
|
6,535 |
|
总营业费用 |
|
|
3,297 |
|
|
|
2,695 |
|
|
|
5,198 |
|
|
|
8,586 |
|
持续经营损失 |
|
|
(1,760 |
) |
|
|
(1,397 |
) |
|
|
(1,369 |
) |
|
|
(4,909 |
) |
利息收入 |
|
|
233 |
|
|
|
133 |
|
|
|
428 |
|
|
|
538 |
|
其他收入,净额 |
|
|
15 |
|
|
|
17 |
|
|
|
168 |
|
|
|
36 |
|
2023年3月PIPE的估值损失 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(6,076 |
) |
普通股warrants和期权负债的公允价值变动 |
|
|
330 |
|
|
|
608 |
|
|
|
493 |
|
|
|
5,965 |
|
分配给负债分类期权的发行和承销费用 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(430 |
) |
继续经营业务的净亏损(税前) |
|
|
(1,182 |
) |
|
|
(639 |
) |
|
|
(280 |
) |
|
|
(4,876 |
) |
所得税费用 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
持续经营的净损失 |
|
|
(1,182 |
) |
|
|
(639 |
) |
|
|
(280 |
) |
|
|
(4,877 |
) |
来自终止经营的净损失 — 身体护理 |
|
|
— |
|
|
|
(83 |
) |
|
|
— |
|
|
|
(591 |
) |
来自终止经营的净损失 — GoodWheat |
|
|
(430 |
) |
|
|
(1,845 |
) |
|
|
(2,694 |
) |
|
|
(5,665 |
) |
净亏损 |
|
|
(1,612 |
) |
|
|
(2,567 |
) |
|
|
(2,974 |
) |
|
|
(11,133 |
) |
归属于少数股东的净亏损 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(5 |
) |
归属于普通股股东的净损失 |
|
$ |
(1,612 |
) |
|
$ |
(2,567 |
) |
|
$ |
(2,974 |
) |
|
$ |
(11,128 |
) |
每股普通股股东应占净亏损: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
来自持续经营的基本和稀释 |
|
$ |
(0.87 |
) |
|
$ |
(0.47 |
) |
|
$ |
(0.21 |
) |
|
$ |
(4.08 |
) |
来自终止经营的基本 |
|
$ |
(0.32 |
) |
|
$ |
(1.42 |
) |
|
$ |
(1.98 |
) |
|
$ |
(5.24 |
) |
归属于普通股股东的每股净亏损(基本和稀释) |
|
$ |
(1.18 |
) |
|
$ |
(1.89 |
) |
|
$ |
(2.18 |
) |
|
$ |
(9.31 |
) |
每股计算中使用的加权平均股数 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
基本和摊薄 |
|
|
1,363,753 |
|
|
|
1,359,511 |
|
|
|
1,362,754 |
|
|
|
1,195,354 |
|
其他综合收入(损失),扣除税后 |
|
|
|
|
|
|
|
|
|
|
|
|
||||
可供出售证券的未实现收益 |
|
$ |
36 |
|
|
$ |
66 |
|
|
$ |
117 |
|
|
$ |
87 |
|
可供出售证券的收益重分类调整计入净损失 |
|
$ |
- |
|
|
$ |
— |
|
|
$ |
(111 |
) |
|
$ |
— |
|
可供出售证券未实现收益的变动 |
|
$ |
36 |
|
|
$ |
66 |
|
|
$ |
6 |
|
|
$ |
87 |
|
全面损失 |
|
$ |
(1,576 |
) |
|
$ |
(2,501 |
) |
|
$ |
(2,968 |
) |
|
$ |
(11,041 |
) |
2
Arcadia生命科学股份有限公司。
合并现金流量表
(未经审计)
(以千为单位)
|
|
截至9月30日的九个月 |
|
|||||
|
|
|
2024 |
|
|
|
2023 |
|
经营活动产生的现金流量: |
|
|
|
|
|
|
||
净亏损 |
|
$ |
(2,974 |
) |
|
$ |
(11,133 |
) |
用于调节净损失和经营活动产生的现金流量的调整项目为: |
|
|
|
|
|
|
||
普通股权证和期权负债的公允价值变动 |
|
|
(493 |
) |
|
|
(5,965 |
) |
分配给负债分类期权的发行和发售费用 |
|
|
— |
|
|
|
430 |
|
2023年3月对PIPE的估值损失 |
|
|
— |
|
|
|
6,076 |
|
折旧费 |
|
|
92 |
|
|
|
227 |
|
租赁摊销 |
|
|
502 |
|
|
|
535 |
|
应收票据折扣的摊销 |
|
|
(90 |
) |
|
|
— |
|
处置固定资产收益 |
|
|
(65 |
) |
|
|
(36 |
) |
出售RS durum小麦特性所得的收益 |
|
|
(4,000 |
) |
|
|
— |
|
基于股票的补偿 |
|
|
395 |
|
|
|
573 |
|
存货减值损失 |
|
|
154 |
|
|
|
444 |
|
财产和设备的减值 |
|
|
36 |
|
|
|
— |
|
运营资产和负债的变化: |
|
|
|
|
|
|
||
应收账款和其他应收款 |
|
|
(445 |
) |
|
|
249 |
|
存货 |
|
|
620 |
|
|
|
(1,388 |
) |
预付费用及其他流动资产 |
|
|
287 |
|
|
|
(284 |
) |
其他非流动资产 |
|
|
— |
|
|
|
(13 |
) |
应付账款和应计费用 |
|
|
(719 |
) |
|
|
(300 |
) |
到相关方款项 |
|
|
(29 |
) |
|
|
(2 |
) |
其他流动负债 |
|
|
(11 |
) |
|
|
11 |
|
营运租赁负债 |
|
|
(678 |
) |
|
|
(573 |
) |
用于经营活动的净现金 |
|
|
(7,418 |
) |
|
|
(11,149 |
) |
投资活动产生的现金流量: |
|
|
|
|
|
|
||
出售房产和设备的收益 |
|
|
342 |
|
|
|
42 |
|
出售Verdeca的收益 — 收到的收益 |
|
|
— |
|
|
|
569 |
|
出售投资所得款 |
|
|
2,501 |
|
|
|
— |
|
出售RS硬质小麦性状的收益 |
|
|
4,000 |
|
|
|
— |
|
与GoodWheat销售相关的现金支付 |
|
|
(2,000 |
) |
|
|
— |
|
购买物业和设备 |
|
|
(16 |
) |
|
|
(5 |
) |
投资购买 |
|
|
— |
|
|
|
(5,002 |
) |
投资活动产生的净现金流量 |
|
|
4,827 |
|
|
|
(4,396 |
) |
筹资活动产生的现金流量: |
|
|
|
|
|
|
||
普通股、预资 warrants 的发行所得 |
|
|
— |
|
|
|
5,997 |
|
与2023年3月PIPE相关的发行费用支付 |
|
|
— |
|
|
|
(497 |
) |
ESPP购买的收入 |
|
|
9 |
|
|
|
12 |
|
融资活动提供的净现金 |
|
|
9 |
|
|
|
5,512 |
|
现金及现金等价物净减少 |
|
|
(2,582 |
) |
|
|
(10,033 |
) |
现金及现金等价物 - 期初余额 |
|
|
6,518 |
|
|
|
20,644 |
|
现金及现金等价物 - 期末余额 |
|
$ |
3,936 |
|
|
$ |
10,611 |
|
现金流量补充资料 |
|
|
|
|
|
|
||
非现金投融资活动: |
|
|
|
|
|
|
||
向配售代理发行的普通股期权,并纳入发行中 |
|
$ |
— |
|
|
$ |
212 |
|
2023年3月的评估损失中包括的warrants和期权修改 |
|
$ |
— |
|
|
$ |
404 |
|
以新经营租赁负债作为交换所获得的权利资产 |
|
$ |
86 |
|
|
$ |
— |
|
因销售GoodWheat确认的应收票据 |
|
$ |
5,705 |
|
|
$ |
— |
|
# # #
3